---
title: "Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002793.SZ.md"
symbol: "002793.SZ"
name: "Luoxin Pharmaceuticals Group Stock Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:50:02.804Z"
locales:
  - [en](https://longbridge.com/en/quote/002793.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002793.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002793.SZ.md)
---

# Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)

## Company Overview

Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers health care services.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.luoxin.cn](https://www.luoxin.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 192 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.78% |  |
| Net Profit YoY | 70.74% |  |
| P/B Ratio | 4.91 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5400153167.93 |  |
| Revenue | 2371190839.84 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -21.65% | E |
| Profit Margin | -11.38% | D |
| Gross Margin | 61.01% | A |
| Revenue YoY | -2.78% | D |
| Net Profit YoY | 70.74% | A |
| Total Assets YoY | -12.64% | E |
| Net Assets YoY | -20.15% | E |
| Cash Flow Margin | -88.20% | E |
| OCF YoY | -2.78% | D |
| Turnover | 0.62 | B |
| Gearing Ratio | 67.07% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Luoxin Pharmaceuticals Group Stock Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.78%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "70.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.91",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5400153167.93",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2371190839.84",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-21.65%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-11.38%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "61.01%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.78%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "70.74%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.64%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-20.15%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-88.20%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-2.78%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.62",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "67.07%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -18.85 | 187/215 | - | - | - |
| PB | 4.63 | 182/215 | 4.27 | 3.84 | 3.64 |
| PS (TTM) | 2.14 | 39/215 | 2.44 | 2.21 | 2.12 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002793.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002793.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002793.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002793.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**